Biotechnology Trends 2026: Multi-Omics, AI Drug Discovery & Biosecurity

Biotechnology in 2026 is defined by a fundamental acceleration. Tools that took decades to develop — gene editing, protein structure prediction, single-cell sequencing — are now being combined with AI to create drug discovery and diagnostic pipelines that would have seemed impossible five years ago. Here is what is actually happening and why it matters for medicine, policy, and everyday health.

AI-Accelerated Drug Discovery: Real Numbers

The pharmaceutical industry has spent decades trying to shorten the drug development timeline. The average time from initial compound identification to FDA approval is still 10–12 years and costs over $2 billion. But the early stages — target identification to clinical candidate — are where AI is making the most measurable impact.

Key milestones in 2025–2026:

• Insilico Medicine's INS018_055 completed Phase II trials for idiopathic pulmonary fibrosis — the first AI-designed drug molecule to reach Phase II. The total design-to-trial timeline was 26 months.
• Recursion Pharmaceuticals reported that its AI platform identified 40 preclinical candidates in 2025 — more than their previous four years combined.
• AlphaFold 3 (DeepMind, 2024) extended protein structure prediction to protein-DNA, protein-RNA, and protein-small molecule interactions, directly supporting computational drug binding prediction.
• Isomorphic Labs (Alphabet) signed drug discovery partnerships with Eli Lilly and Novartis totaling over $3 billion in milestone payments — the largest commercial validation of AI drug discovery to date.

The limitation remains clinical trial success rates. AI improves the speed and efficiency of preclinical work, but clinical failure rates (Phase I to approval) remain approximately 90% — similar to conventional programs. The industry is now applying AI to clinical trial design and patient stratification to address this bottleneck.

---

Multi-Omics: Building a Complete Biological Picture

Single biomarkers (one gene, one protein, one metabolite) rarely explain complex diseases. Multi-omics integrates multiple data layers:

Layer	What It Measures	Technology
Genomics	DNA sequence variations	Whole genome sequencing, SNP arrays
Transcriptomics	Gene expression (RNA levels)	RNA sequencing (RNA-seq)
Proteomics	Protein abundance and modifications	Mass spectrometry
Metabolomics	Small molecule metabolites	NMR spectroscopy, mass spectrometry
Epigenomics	DNA methylation, histone modifications	ATAC-seq, ChIP-seq

Clinical applications gaining traction in 2026:

Cancer subtyping: Multi-omics can distinguish molecular subtypes of cancer that look identical under a microscope but respond very differently to treatment. The TCGA (The Cancer Genome Atlas) expanded its multi-omics database in 2025 to cover 33 cancer types with full genomic, transcriptomic, and proteomic profiles.

Early Alzheimer's detection: A 2025 Nature Aging study demonstrated that a plasma multi-omics panel (proteins + metabolites) detected Alzheimer's pathology 8–10 years before cognitive symptoms with 89% accuracy — compared to 73% for amyloid PET scanning.

Microbiome-disease connections: Metagenomic sequencing combined with metabolomics is mapping how gut bacteria influence drug metabolism, immune response, and psychiatric conditions. A 2025 Cell paper identified specific microbiome signatures that predict anti-depressant response — a potential route to precision psychiatry.

---

CRISPR Therapeutics: From Approval to Pipeline

Casgevy (exa-cel), the first CRISPR-based therapy approved by the FDA (December 2023), treats sickle cell disease and transfusion-dependent beta-thalassemia. In 2025:

• Over 800 patients had been treated with Casgevy worldwide
• Long-term follow-up data showed sustained hemoglobin F elevation in 97% of patients at 24 months
• List price: $2.2 million per one-time treatment

The pipeline beyond Casgevy:

Program	Company	Target Disease	Stage (June 2026)
NTLA-2001	Intellia Therapeutics	Hereditary transthyretin amyloidosis	Phase III
RG6346 (in vivo)	Roche/Intellia	Hepatitis B (functional cure)	Phase II
Ex vivo CAR-T + CRISPR	Multiple	B-cell lymphoma, leukemia	Multiple Phase II/III
Prime editing (PE6)	Prime Medicine	Alpha-1 antitrypsin deficiency	Phase I

In vivo vs. ex vivo delivery remains the central technical challenge. Most approved and late-stage CRISPR therapies are ex vivo (cells are removed, edited, and reinfused). In vivo delivery — editing genes directly inside the body — requires solving the problem of getting CRISPR machinery to the right cells without triggering immune responses or off-target edits.

---

Point-of-Care Diagnostics: Testing Anywhere

The COVID-19 pandemic accelerated at-home diagnostic development by approximately 10 years. In 2026, the diagnostic landscape has expanded well beyond respiratory viruses:

• CLIA-waived at-home STI panels: FDA approved the first at-home gonorrhea/chlamydia test (Cue Health) in 2024; multiple competitors launched in 2025
• Continuous glucose monitoring (CGM) without prescription: Dexterity and similar devices now approved for non-diabetic users monitoring metabolic health
• Wearable cardiac monitoring: Apple Watch Series 10 (2025) received FDA clearance for Afib history feature; AliveCor KardiaMobile 6L cleared for 6-lead ECG analysis
• Gut microbiome testing: Direct-to-consumer microbiome analysis (Viome, Biohm) now includes multi-omics-based personalized dietary recommendations

The regulatory challenge is quality control at scale: at-home tests often have lower sensitivity/specificity than laboratory tests, and consumers may not understand how to interpret results. The FDA's 2025 guidance on direct-to-consumer diagnostic labeling aims to standardize accuracy disclosure requirements.

---

Biosecurity: The Policy Problem AI Creates

The same computational tools that accelerate beneficial biotechnology also lower the barrier to designing harmful biological agents. This dual-use problem has moved from academic discussion to active policy debate.

A 2024 study from MIT's Kevin Esvelt group demonstrated that AI large language models could provide meaningful technical assistance to individuals attempting to work with select agents — published after responsible disclosure to US biosecurity officials.

Current regulatory response:

• Executive Order 14110 (AI): Required frontier AI developers to report model capabilities related to biosecurity to the Department of Homeland Security
• Screening mandate (2025): The National Security Council issued guidance requiring AI developers to implement screening for biosecurity-risk outputs — the first AI-specific biosecurity requirement
• Biosecurity Innovation and Reform Act of 2025: Under Senate review as of June 2026; would mandate enhanced screening and reporting for AI systems used in life sciences research

The scientific community is largely supportive of oversight, but debates remain about how to prevent biosecurity restrictions from hampering legitimate research. The Global Health Security Index rates only 13 countries as "adequately prepared" for a biosecurity incident involving enhanced pathogens.

AI in healthcare: how machine learning is changing diagnosis and treatment →

Extreme heat health risks 2026: the science and practical guidance →